RE: One question from rns14 Apr 2021 08:40
The Company has now received notice from GlobalCo that it will not exercise its option to license the Company's intellectual property. Accordingly, the Company has given notice to GlobalCo of its intention to exercise its own option to license GlobalCo's intellectual property on an exclusive, worldwide basis. The Company continues to work actively with GlobalCo in relation to development of the antibody, and to negotiate with GlobalCo to determine the exact terms of the licence and GlobalCo's continued involvement in the progression of CDX toward clinical trials. Further announcements will be made in due course.
M8s rates coming